Anti-Alpha-synuclein antibody (ab21976)
Key features and details
- Sheep polyclonal to Alpha-synuclein
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Alpha-synuclein antibody
See all Alpha-synuclein primary antibodies -
Description
Sheep polyclonal to Alpha-synuclein -
Host species
Sheep -
Tested Applications & Species
See all applications and species dataApplication Species IHC-P Human
-
Immunogen
Synthetic peptide corresponding to Human Alpha-synuclein.
Sequence:PQEGILEDMPVDP
-
General notes
This antibody achieves excellent staining of Lewy bodies in Parkinson’s disease and Dementia with Lewy bodies disease tissue and gives excellent staining of glial inclusions in Multi System Atrophy tissue.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Concentration information loading... -
Purity
Whole antiserum -
Purification notes
This product is supplied as filtered serum. -
Primary antibody notes
This antibody achieves excellent staining of Lewy bodies in Parkinson’s disease and Dementia with Lewy bodies disease tissue and gives excellent staining of glial inclusions in Multi System Atrophy tissue. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab21976 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| IHC-P |
Human
|
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P |
1/1000 - 1/4000. Antigen retrieval has been used in characterisation but may not be necessary.
1) Slide holder containing 1mM EDTA at pH 8 is boiled in a microwave (~2min).
2) Slides are placed in holder and boiled for a further 10 min with the microwave on low.
3) Slides allowed to cool before use.
|
| Notes |
|---|
|
IHC-P
1/1000 - 1/4000. Antigen retrieval has been used in characterisation but may not be necessary. 1) Slide holder containing 1mM EDTA at pH 8 is boiled in a microwave (~2min). 2) Slides are placed in holder and boiled for a further 10 min with the microwave on low. 3) Slides allowed to cool before use. |
Target
-
Function
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. -
Tissue specificity
Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. -
Involvement in disease
Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Parkinson disease 1
Parkinson disease 4
Dementia Lewy body -
Sequence similarities
Belongs to the synuclein family. -
Domain
The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments. -
Post-translational
modificationsPhosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure. -
Cellular localization
Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons. - Information by UniProt
-
Database links
- Entrez Gene: 6622 Human
- Omim: 163890 Human
- SwissProt: P37840 Human
- Unigene: 21374 Human
-
Alternative names
- Alpha synuclein antibody
- Alpha-synuclein antibody
- Alpha-synuclein, isoform NACP140 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Alpha-synuclein antibody (ab21976)ab21976 staining Lewy body in Dementia with Lewy body disease tissue at 1/1000 dilution by Immunohistochemistry (FFPE-sections). Secondary antibody biotinylated Donkey and sheep followed by Vector ABC and DAB substrate.
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab21976 has been referenced in 2 publications.
- McGlinchey RP et al. C-terminal a-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease. J Biol Chem 294:9973-9984 (2019). PubMed: 31092553
- Yap TL et al. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 286:28080-8 (2011). PubMed: 21653695